---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Pathophysiology"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Pathophysiology. Topics: Primary aldosteronism: renin-independent aldosterone production and volume expansion, Continuum of renin-independent aldosterone production across blood pressure categories, Mineralocorticoid receptor activation and target organ injury, Aldosterone excess and intravascular volume expansion in resistant hypertension, and 4 further topics. 8 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/pathophysiology"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Pathophysiology

<a id="heading-2.2.1.4"></a>

## 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

### Primary aldosteronism: renin-independent aldosterone production and volume expansion

> “Primary aldosteronism is defined as a group of disorders in which aldosterone production is inappropriately high for sodium and volume status, is relatively autonomous of the major regulators of aldosterone secretion (angiotensin II and potassium), and cannot be completely suppressed with sodium loading.”
> “The increased production of aldosterone induces intravascular volume expansion, suppressed plasma renin activity, sodium retention, increased potassium excretion, hypertension, and cardiovascular and kidney damage.”
> “Primary aldosteronism is a common cause of secondary hypertension (occurring in 5% to 10% of patients with hypertension and 20% of patients with resistant hypertension), and targeted treatment is associated with improved kidney and cardiovascular outcomes.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.4-2"></a>

### Continuum of renin-independent aldosterone production across blood pressure categories

> “Participants with normotension (n = 289), stage 1 hypertension (n = 115), stage 2 hypertension (n = 203), and resistant hypertension (n = 408).”
> “Every blood pressure category had a continuum of renin-independent aldosterone production, where greater severity of production was associated with higher blood pressure, kaliuresis, and lower serum potassium levels.”
> “Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension”
> “Beyond this categorical definition of primary aldosteronism, there is a prevalent continuum of renin-independent aldosterone production that parallels the severity of hypertension.”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

<a id="topic-2.2.1.4-3"></a>

### Mineralocorticoid receptor activation and target organ injury

> “This renin-independent aldosterone production can cause hypertension, but interactions with the mineralocorticoid receptor also cause hypokalemia and increased risk for adverse cardiovascular outcomes”

Source: [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)

> “Chronic renin-angiotensin-aldosterone system activation and excess aldosterone exert detrimental effects on the heart and the kidneys via contributing to inflammation, fibrosis, and dysfunction in the myocardium, vasculature, and the kidneys.”
> “These effects are purported to be through genomic mineralocorticoid receptor (MR)-mediated, nongenomic MR-dependent, and nongenomic non-MR dependent actions.”
> “Because both hyperkalemia and excess aldosterone are associated with progression of CKD and HF, and MRA therapy is associated with elevations in aldosterone levels, patients on MRA therapy may remain at a high residual risk for poor outcomes even on MRA therapy.”

Source: [Fioretti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40738563/)

> “Patients with primary aldosteronism are at greater risk for target organ damage than those with primary hypertension due to the toxic tissue effects of aldosterone even when adjusted for degree of hypertension.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.4-4"></a>

### Aldosterone excess and intravascular volume expansion in resistant hypertension

> “Consecutive subjects with resistant hypertension (RHTN) (n=279) and controls (n=53) were prospectively evaluated for plasma aldosterone (PAC), plasma renin activity (PRA), aldosterone-renin ratio (ARR), brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), 24-hr urinary aldosterone (UAldo), cortisol (UCort), sodium (UNa) and potassium (UK) on their routine diet.”
> “PAC (13±0.5 vs. 8.4±0.7 ng/dl, p=0.0005), ARR (22±1.7 vs. 6±0.7, p < 0.0001), UAldo (13±0.6 vs. 9.7±0.9 μg/24hr, p=0.02), BNP (37.2±3.1 vs. 22.5±3.4 pg/ml, p=0.007) and ANP (95.9±5.8 vs. 54.8±4.9 pg/ml, p=0.001) were higher, PRA (2.3±0.2 vs. 3.8±0.9 ng/ml/hr, p=0.02) and serum potassium (3.9±0.03 vs. 4.3±0.06 mEq/L, p < 0.0001) were lower in patients with RHTN compared to controls.”
> “These findings indicate that aldosterone levels are higher and there is evidence of intravascular volume expansion (higher BNP and ANP levels) in patients with resistant hypertension compared to controls.”

Source: [Gaddam et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2748247/)

<a id="topic-2.2.1.4-5"></a>

### Renin suppression and sodium retention in resistant hypertension

> “and suppressed circulating renin levels (≈60% of those with RH have suppressed renin levels).”
> “In general, RH is characterized by exquisite salt sensitivity of BP.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Home systolic blood pressure reduction by spironolactone was predicted by ARR (r2=0·13, p<0·0001) and plasma renin (r2=0·11, p=0·00024).”
> “Thus, 31 (25% [95% CI 17–33]) of 126 patients were deemed to have inappropriately high aldosterone concentrations.”
> “Thoracic fluid content was reduced by 6·8% from baseline (95% CI 4·0 to 8·8; p<0·0001) with spironolactone, but not other treatments.”
> “Our results suggest that resistant hypertension is commonly a salt-retaining state, most likely due to inappropriate aldosterone secretion.”
> “Mineralocorticoid receptor blockade by spironolactone overcomes the salt retention and resistance of hypertension to treatment.”

Source: [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)

<a id="topic-2.2.1.4-6"></a>

### Obesity: visceral adiposity and mineralocorticoid activity

> “Visceral adiposity in particular plays a fundamental role in causing high BP through a variety of mechanisms culminating in enhanced salt sensitivity, vascular dysfunction, and activation of the sympathetic nervous system and renin-angiotensin system.”
> “Mounting evidence further supports the importance of heightened mineralocorticoid activity in RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Multiple cohort studies have identified common risk factors for resistant hypertension, including older age, obesity, CKD, and diabetes.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-2.2.1.4-7"></a>

### Chronic kidney disease: impaired sodium excretion and volume expansion

> “CKD is both a cause and a complication of poorly controlled hypertension.”
> “Reduced kidney function results in impaired salt excretion, overactivation of the renin-angiotensin-aldosterone system, increased sympathetic nervous system activity, and altered medication efficacy.”
> “Treatment resistance in patients with CKD is undoubtedly related in large part to increased sodium and fluid retention and consequential intravascular volume expansion.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

<a id="topic-2.2.1.4-8"></a>

### Obstructive sleep apnea: fluid retention and aldosterone excess

> “OSA is extremely common in patients with RH, with prevalence rates as high as 70% to 90%, and when present, OSA is often severe.”
> “The high occurrence of OSA in patients with RH has been attributed to increased fluid retention and accompanying upper airway edema, as suggested by studies positively relating the presence and severity of OSA to aldosterone excess and high dietary sodium intake.”
> “The role of aldosterone in promoting OSA is additionally supported by studies demonstrating that mineralocorticoid receptor antagonists reduce the severity of OSA in patients with RH.”

Source: [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)

> “Additionally, patients with resistant hypertension (regardless of whether hypokalemia is present), hypertension with hypokalemia (either spontaneous or diuretic-induced), and hypertension with OSA have a relatively high prevalence of primary aldosteronism (∼20%-35%).”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
